P523 Improvement of quality of life and continence in patients with distal ulcerative colitis treated by mesalazine: QUARTZ study
ECCO'20 Vienna
2020
P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey
ECCO'20 Vienna
2020
P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study
ECCO'20 Vienna
2020
P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease
ECCO'20 Vienna
2020
P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre
ECCO'20 Vienna
2020
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
ECCO'20 Vienna
2020
P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service
ECCO'20 Vienna
2020
P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis
ECCO'20 Vienna
2020
P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease
ECCO'20 Vienna
2020
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
ECCO'20 Vienna
2020
P536 Early prediction of intravenous corticosteroid therapy failure in moderate–severe ulcerative colitis
ECCO'20 Vienna
2020
P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry
ECCO'20 Vienna
2020
P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab
ECCO'20 Vienna
2020